Camp4 Therapeutics Future Growth
Future criteria checks 2/6
Camp4 Therapeutics's earnings are forecast to decline at 8.7% per annum while its annual revenue is expected to grow at 71% per year. EPS is expected to grow by 107.6% per annum. Return on equity is forecast to be -72.1% in 3 years.
Key information
-8.7%
Earnings growth rate
107.6%
EPS growth rate
| Biotechs earnings growth | 28.3% |
| Revenue growth rate | 71.0% |
| Future return on equity | -72.1% |
| Analyst coverage | Low |
| Last updated | 22 Nov 2024 |
Recent future growth updates
No updates
Recent updates
No updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | N/A | -60 | -61 | -61 | 3 |
| 12/31/2025 | 0 | -59 | -60 | -63 | 4 |
| 12/31/2024 | 0 | -49 | -49 | -49 | 3 |
| 9/30/2024 | N/A | -52 | -46 | -46 | N/A |
| 6/30/2024 | 0 | -50 | -44 | -43 | N/A |
| 3/31/2024 | 0 | -50 | -44 | -44 | N/A |
| 12/31/2023 | 0 | -49 | -45 | -44 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CAMP is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CAMP is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CAMP is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CAMP's revenue (71% per year) is forecast to grow faster than the US market (8.9% per year).
High Growth Revenue: CAMP's revenue (71% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CAMP is forecast to be unprofitable in 3 years.